| Drew Mahoney I, MD | |
|
820 E 17th St, Cheyenne, WY 82001-4714 | |
| (307) 632-2434 | |
| Not Available |
| Full Name | Drew Mahoney I |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 820 E 17th St, Cheyenne, Wyoming |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740807551 | NPI | - | NPPES |
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
Fostering innovation to speed the improvement of health care is the goal of an $8.3 million grant to researchers at Cincinnati Children's Hospital Medical Center.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has entered into separate Warrant Exchange Agreements with each of the holders of outstanding warrants originally issued in March 2010 to eliminate all of such warrants having "ratchet" price-based anti-dilution protection features in exchange for shares of Company common stock and a lower number of warrants having no price based anti-dilution protections.
In research published in Biochemical and Biophysical Research Communications, Saint Louis University researchers describe a technology that can detect new, previously unknown viruses. The technique offers the potential to screen patients for viruses even when doctors have not identified a particular virus as the likely source of an infection.
Indoor spraying with the insecticide bendiocarb has dramatically decreased malaria transmission in many parts of Benin, new evidence that insecticides remain a potent weapon for fighting malaria in Africa despite the rapid rise of resistance to an entire class of mosquito-killing compounds, according to a study published today in the October edition of The American Journal of Tropical Medicine and Hygiene.
Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Drew Mahoney I, MD 820 E 17th St, Cheyenne, WY 82001-4714 Ph: (307) 632-2434 | Drew Mahoney I, MD 820 E 17th St, Cheyenne, WY 82001-4714 Ph: (307) 632-2434 |
News Archive
Fostering innovation to speed the improvement of health care is the goal of an $8.3 million grant to researchers at Cincinnati Children's Hospital Medical Center.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has entered into separate Warrant Exchange Agreements with each of the holders of outstanding warrants originally issued in March 2010 to eliminate all of such warrants having "ratchet" price-based anti-dilution protection features in exchange for shares of Company common stock and a lower number of warrants having no price based anti-dilution protections.
In research published in Biochemical and Biophysical Research Communications, Saint Louis University researchers describe a technology that can detect new, previously unknown viruses. The technique offers the potential to screen patients for viruses even when doctors have not identified a particular virus as the likely source of an infection.
Indoor spraying with the insecticide bendiocarb has dramatically decreased malaria transmission in many parts of Benin, new evidence that insecticides remain a potent weapon for fighting malaria in Africa despite the rapid rise of resistance to an entire class of mosquito-killing compounds, according to a study published today in the October edition of The American Journal of Tropical Medicine and Hygiene.
Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.
› Verified 9 days ago
Dr. Kristine K Van Kirk, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6015 Sycamore Rd, Cheyenne, WY 82009 Phone: 307-823-2968 | |
Dr. Christian Alexander Flanders, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 E 17th St, Cheyenne, WY 82001 Phone: 307-632-2434 Fax: 307-634-3510 | |
Dr. Bradley Mohar, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 214 E 23rd St, Cheyenne, WY 82001 Phone: 307-634-2273 | |
Dr. Douglas W Edgren, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1331 Prairie Ave Ste 1, Cheyenne, WY 82009 Phone: 307-632-0728 | |
Zachary Dale Herman, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 E 17th St, Cheyenne, WY 82001 Phone: 307-632-2434 Fax: 307-635-3510 | |
Margaret Ann Lembitz, NP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3229 E Pershing Blvd, Cheyenne, WY 82001 Phone: 307-363-2054 Fax: 307-227-6817 | |
Benjamin Leishman, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 E 17th St, Cheyenne, WY 82001 Phone: 307-632-2434 |